1st Order Pharmaceuticals, Inc.

Biopharma companies work hard to stack their pipelines with promising candidates. But which candidates are the most promising? A recent report from Evaluate finds that the top three pipeline assets

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

Biopharma start-up fundraising more than doubled to $3.87bn in the second quarter versus the prior quarter, helped by initial public offerings, including the Actelion Pharmaceuticals Ltd. spinout

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in